Chemed Corporation
NYSE:CHEMedical - Care Facilities
+$4.91 today
- Market cap
- $7.12B
- Beta
- 0.54
- P/E (TTM)
- 23.2
- EPS (TTM)
- $19.00
- Dividend yield
- 0.54%
Volume 0.17M
Average 0.25M
CHE Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Chemed CorporationNYSE: CHE
Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other current liabilities rises 27.0% from a year ago
Other current liabilities stood at $130.06M at the end of Q2 FY2026, up 27.0% from a year earlier and up 5.3% from the prior quarter. Over 3 fiscal years it compounded at -6.0% a year.
Context
- Other current liabilities amounted to 8.2% of total assets at the end of Q2 FY2026, up 2.3 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +27.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 120.95M USD
- Year-over-year change
- -10.2%
- 4-year CAGR
- -2.6%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 120.95M | -10.2% |
| FY2024 | 2024-12-31 | 134.75M | +10.6% |
| FY2023 | 2023-12-31 | 121.87M | -16.4% |
| FY2022 | 2022-12-31 | 145.84M | +8.3% |
| FY2021 | 2021-12-31 | 134.63M | — |
Other Current Liabilities vs competitors
How CHE compares with its peers on the latest reported figures
- CHE's Jun 2026 other current liabilities of $130.06M is the highest of the 5 companies compared; the peer median is $37.63M.
- Its year-over-year change of +27.0% is the highest of 5, against a peer median of -39.9%.
- Other current liabilities amounts to 8.2% of total assets for CHE, versus a peer median of 1.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $130.06M | +27.0% | -6.0% | 8.2% | |
| Oct 2026 | $83.18M | -65.9% | -45.3% | 3.8% | |
| Sep 2026 | $62.35M | -14.0% | -5.8% | 1.8% | |
| Jun 2026 | $12.91M | -3.0% | +31.9% | 0.9% | |
| Mar 2026 | $0 | -100.0% | -31.4% | 0.0% | |
| Peer median (excluding CHE) | $37.63M | -39.9% | -18.6% | 1.3% | |
Competitors are the stored peer set for CHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32.9M | 74.13M | 263.96M | 178.35M | 74.52M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 137.22M | 139.41M | 181.51M | 171.16M | 182.58M |
| Inventory | 10.11M | 10.27M | 12M | 8.19M | 7.54M |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 230.29M | 272.61M | 500.84M | 394.75M | 302.62M |
| Property, Plant & Equipment (Net) | 318.73M | 335.38M | 330.23M | 328.16M | 336.81M |
| Goodwill | 578.59M | 581.3M | 585.02M | 666.74M | 667M |
| Intangible Assets | 108.1M | 99.73M | 90.26M | 92.21M | 82.76M |
| Long-term Investments | 98.88M | 0 | 0 | 0 | 140.35M |
| Tax Assets | 0 | 0 | 0 | 0 | 101.82M |
| Other Non-current Assets | 8.14M | 153M | 161.74M | 186.72M | 8.65M |
| Total Non-current Assets | 1.11B | 1.17B | 1.17B | 1.27B | 1.34B |
| Total Assets | 1.34B | 1.44B | 1.67B | 1.67B | 1.64B |
| Account Payables | 73.02M | 41.88M | 64.03M | 44.15M | 53.46M |
| Short-term Debt | 0 | 5M | 15.7M | 0 | 51.89M |
| Tax Payables | 41K | 18.52M | 6.86M | 7.59M | 11.17M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 134.63M | 145.84M | 121.87M | 134.75M | 120.95M |
| Total Current Liabilities | 302.4M | 297.21M | 312.05M | 285.7M | 287.13M |
| Long-term Debt | 185M | 92.5M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 23.18M | 38.61M | 30.32M | 25.95M | 121.14M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 136.14M |
| Other Non-current Liabilities | 108.24M | 104.47M | 117.07M | 139.4M | 13.34M |
| Total Non-current Liabilities | 417.05M | 346.09M | 248.17M | 263.89M | 373.48M |
| Total Liabilities | 719.45M | 643.3M | 560.22M | 549.58M | 660.61M |
| Common Stock | 36.51M | 36.8M | 37.18M | 37.42M | 37.6M |
| Retained Earnings | 1.97B | 2.2B | 2.45B | 2.72B | 2.96B |
| Accumulated OCI | 0 | 0 | 0 | 0 | 2.36M |
| Other Stockholders Equity | 2.2M | 2.25M | 2.08M | 2.22M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 623.27M | 798.72M | 1.11B | 1.12B | 979.41M |
| Total Debt | 323.54M | 247.01M | 155.11M | 140.84M | 154.76M |
| Net Debt | 290.65M | 172.88M | (108.85M) | (37.51M) | 80.24M |
Chemed Corporation
NYSE:CHE
Intrinsic Alpha fair value
Locked
Current Price
$546.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.